Oxaliplatin-associated hypersensitivity reactions: clinical presentation and management

Area of Science:

• Oncology
• Clinical Pharmacology

Background:

• Hypersensitivity reactions (HSRs) to platinum-based chemotherapy agents like cisplatin and carboplatin are well-documented, occurring in 10%-27% of patients.
• Initial reports suggested a low incidence of HSRs to oxaliplatin, but recent data indicate a similar rate to earlier platinum agents.

Purpose of the Study:

• To review the incidence and management strategies for hypersensitivity reactions to oxaliplatin.
• To discuss re-exposure protocols following hypersensitivity reactions to oxaliplatin.

Main Methods:

• Literature review of hypersensitivity reactions to oxaliplatin.
• Analysis of clinical management approaches for varying degrees of hypersensitivity.

Main Results:

• The incidence of oxaliplatin hypersensitivity reactions appears comparable to cisplatin and carboplatin.
• Reactions range from mild flushing to severe anaphylaxis.
• Management strategies include immunosuppression and prolonged infusion for mild reactions; alternative therapies are preferred for severe reactions.

Conclusions:

• Hypersensitivity reactions to oxaliplatin require careful management based on severity.
• Re-challenge with oxaliplatin may be considered after desensitization or immunosuppression for mild reactions, with careful risk-benefit assessment.
• Alternative treatments should be explored for patients experiencing moderate-to-severe hypersensitivity reactions.